Comments
Loading...
PharmaCom BioVet Analyst Ratings and Price Targets | OTC:PHMB | Benzinga
PharmaCom BioVet Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for PharmaCom BioVet Corp from these most-recent analyst ratings.
Analyst Ratings for PharmaCom BioVet
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
No data available to display | |||||||||
FAQ
What is the target price for PharmaCom BioVet (PHMB) stock?
There is no price target for PharmaCom BioVet
What is the most recent analyst rating for PharmaCom BioVet (PHMB)?
There is no analyst for PharmaCom BioVet
When was the last upgrade for PharmaCom BioVet (PHMB)?
There is no last upgrade for PharmaCom BioVet
When was the last downgrade for PharmaCom BioVet (PHMB)?
There is no last downgrade for PharmaCom BioVet.
When is the next analyst rating going to be posted or updated for PharmaCom BioVet (PHMB)?
There is no next analyst rating for PharmaCom BioVet.
Is the Analyst Rating PharmaCom BioVet (PHMB) correct?
There is no next analyst rating for PharmaCom BioVet.
Browse analyst ratings and price targets on all stocks.
